{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$5.85 vs. cons $5.74",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$11.90B vs. cons $11.72B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic Revenue Growth (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~3.5% vs. cons ~3.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$25.05 (raised range) vs. cons $24.84 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$47.7B midpoint (range $47.3-48.1B reaffirmed) vs. cons $47.8B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Organic growth trajectory / H2 step-up",
      "prediction": "UNCHANGED",
      "answer": "guide ~3%-4% organic reaffirmed vs. cons ~3.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Microbiology divestiture revenue/EPS impact",
      "prediction": "LOWER",
      "answer": "guide ~-$300M revenue / neutral-to-slightly dilutive EPS vs. cons ~$0 baked-in impact (H2 2026 close)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.3,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.8,
  "day5_path": "FADE",
  "day5_rationale": "Beat-and-raise on Q2 headline numbers should drive an initial pop, but the FY guide raise is likely to look 'in-line' relative to the magnitude of the Q2 beat once analysts back out the Clario/microbiology divestiture mechanics and roll forward organic growth assumptions for H2 (China/academic still soft, tariff cushion being drawn down). That combination \u2014 a smaller-than-expected raise to the out-year numbers plus lingering NIH/China/academic uncertainty \u2014 typically causes the initial pop to fade over the following days as sell-side models get trued up rather than meaningfully upgraded.",
  "day5_confidence": "MEDIUM"
}